Executive Summary

In February 2026, MARA published 37 rating actions. The month was notable not only for volume, but for compression of the rating profile into the lower-middle bands. One asset was assigned A (Strong), 15 were assigned B++ (Marginal), and 21 were assigned B+ (Very Weak). One formal downgrade was also recorded.

That distribution is informative. February was a large surveillance month, but not a strong-rating month. The evidence entering the framework was often sufficient to support clinical interest, yet rarely sufficient to establish strong reimbursement probability.

The dominant reimbursement signal for February was therefore not failure. It was finely balanced access with substantial exposure to pricing, comparator, and evidence-maturity constraints.

Trigger and Structural Context

The February cohort spanned ophthalmology, neurology, nephrology, immunology, oncology, pulmonology, endocrinology, hematology, dermatology, infectious disease, and cardiology. The therapeutic breadth was wide, but the structural logic was consistent.

Most assets were early commercial or pre-HTA-stage candidates with encouraging efficacy data and incomplete payer-facing support. In several cases, pivotal trials established activity against placebo or vehicle, but did not yet resolve the questions HTA bodies typically prioritize: appropriate comparator selection, durability, utility capture, and cost-utility defensibility.

This is where reimbursement discipline becomes most useful. Clinical success and commercial access are not interchangeable. In competitive or budget-sensitive categories, even modest weaknesses in comparative positioning can materially affect reimbursement probability.

Domain-Level Drivers

Clinical Effectiveness was often adequate, and in some cases strong. Atrasentan, Clesrovimab, Fitusiran, Sepiapterin, and Nerandomilast all entered February with evidence packages capable of supporting favorable clinical judgments. Yet favorable clinical judgment did not usually translate into strong overall ratings.

The reason was the same across much of the month: weak conversion of clinical evidence into HTA-ready reimbursement support.

Comparator Appropriateness mattered. Assets assessed against placebo, vehicle, or single-arm benchmarks often remained constrained at B++ or B+, even when the efficacy signal was positive. In ophthalmology, oncology, and rare disease settings, lack of direct comparison to relevant standard care repeatedly limited upward movement.

Health-Related Quality of Life remained underdeveloped across much of the cohort. Many February assets had either no validated utility evidence or only narrow symptom-based instruments without direct translation into a robust QALY narrative. That weakens cost-utility anchoring even when clinical effect is real.

Cost-Effectiveness was the principal bottleneck. For a large share of February ratings, no published ICERs, cost-utility models, or usable economic evaluations were available. In a standardized reimbursement framework, that does not create neutral space. It reduces confidence and increases negotiation sensitivity.

The one A rating in February, Avacopan, stood apart because it was supported by a more complete reimbursement case, including a NICE-aligned cost-effectiveness position. That difference is instructive. The gap between A and B++ was often not scientific novelty. It was evidence completeness under payer scrutiny.

February also included a formal downgrade for CagriSema to B++. That action reflected comparative positioning pressure following head-to-head evidence that did not fully support the expected reimbursement advantage. In obesity, where comparative outcomes increasingly shape cost-utility expectations, even a modest shift in positioning can alter the reimbursement signal materially.

What the Ratings Mean

A (Strong) indicates a strong probability of broad reimbursement under HTA scrutiny.

B++ (Marginal) indicates that reimbursement remains achievable but finely balanced, especially where price corridor sensitivity or comparator exposure is high.

B+ (Very Weak) indicates a lower probability of reimbursement, with greater risk of restriction, delay, price pressure, or rejection.

These labels describe reimbursement probability, not regulatory viability.

Structural Implications for Stakeholders

For market access teams, February reinforces a persistent issue: internal forecasts often overestimate reimbursement success when they overweight efficacy and underweight economic maturity.

For M&A and portfolio strategy, the February set is a reminder that a crowded pipeline does not automatically imply a strong reimbursable pipeline. Without an external benchmark, diligence can become structured groupthink.

If this pricing or launch decision is later challenged, what independent benchmark was relied upon?

Methodological Integrity

Each February action reflects application of the same structured framework used across all assets, supporting comparability across months, indications, and portfolios. The framework is calibrated to historical HTA outcomes, based on public evidence, and maintained through continuous surveillance.

February 2026 Ratings Issued

A: Avacopan
B++: Atrasentan, CagriSema, Depemokimab, Difamilast, Donidalorsen, Elinzanetant, Etripamil, Fitusiran, Kygevvi, Nerandomilast, Plozasiran, Remibrutinib, Sebetralstat, Sepiapterin, Sibeprenlimab
B+: Aceclidine, Acoltremon, Asundexian, Avutometinib plus defactinib, Clesrovimab, Copper histidinate, Elamipretide, Gepotidacin, Imlunestrant, Lerodalcibep, Linvoseltamab, Narsoplimab, Paltusotine, Penpulimab, Sevabertinib, Taletrectinib, Telisotuzumab vedotin, Tradipitant, Ziftomenib, Zoliflodacin, Zongertinib

MARA will continue to monitor material evidence events and adjust the reimbursement risk signal accordingly.